Bifunctional Mechanism

For more than 50 years, standard treatment for gout has started with a drug that reduces uric acid production (allopurinol) – an inhibitor of an enzyme known as xanthine oxidase. However, a large percentage of patients do not respond to allopurinol, and then a second drug is added that promotes urinary excretion of uric acid by inhibiting an enzyme known as URAT1.
In our discovery research, Relburn found that the marked reduction in serum uric acid with RLBN1001 owed to its bifunctional inhibition of both enzyme targets – a unique effect never before described. Moreover, the level of inhibition against both targets with RLBN1001 exceeded the standard agents that inhibited only one target.